Morton R P
J Laryngol Otol. 1984 Aug;98(8):819-28. doi: 10.1017/s0022215100147516.
A postal survey of 100 members of the Association of Head and Neck Oncologists of Great Britain was conducted in the first 6 months of 1983. The sample consisted principally of Otolaryngologists (50 per cent), Radiotherapists (14 per cent), Medical Oncologists (10 per cent), Oral Surgeons (10 per cent) and Plastic Surgeons (10 per cent). More than 80 per cent of those who completed the questionnaire used chemotherapy for Head and Neck cancer (72 per cent used it for palliation, and 64 per cent as part of combined modality therapy). There was great variation in the chemotherapeutic regimens used by the various responders. Furthermore, most responders used more than one regimen. Methotrexate was the agent most frequently used. No specific regimen, either single-agent or multiple-agent, enjoyed universal acceptance, although the combination of Vincristine, Bleomycin and Methotrexate was popular. Chemotherapy was thought by most responders to have a useful but as yet undefined place in the management of Head and Neck cancer. This survey underlines the need for prospective, controlled, clinical trials into the efficacy of cytotoxic chemotherapy for Head and Neck cancer.
1983年头6个月对英国头颈肿瘤学家协会的100名成员进行了一次邮政调查。样本主要由耳鼻喉科医生（50%）、放疗科医生（14%）、肿瘤内科医生（10%）、口腔外科医生（10%）和整形外科医生（10%）组成。完成问卷的人中，超过80%的人对头颈癌使用化疗（72%用于姑息治疗，64%作为综合治疗模式的一部分）。不同应答者使用的化疗方案差异很大。此外，大多数应答者使用不止一种方案。甲氨蝶呤是最常用的药物。没有一种特定的方案，无论是单药还是多药方案，能得到普遍认可，尽管长春新碱、博来霉素和甲氨蝶呤的联合方案很受欢迎。大多数应答者认为化疗在头颈癌的治疗中有一定作用，但作用尚未明确。这项调查强调了对头颈癌细胞毒性化疗疗效进行前瞻性、对照临床试验的必要性。
